Met（c-Met） Antibody (YA5575)

Membrane; Single-pass type I membrane protein; Secreted

Tissue_specificity:It is expressed in normal hepatocytes, as well as in the epithelial cells of the stomach, small intestine, and large intestine. It is also present in the basal keratinocytes of the esophagus and skin. Higher concentrations are found in the liver, gastrointestinal tract, thyroid gland, and kidneys. It is also expressed in brain tissue. It is also expressed in the metaphysis (protein level) (PubMed:26637977) .

c-Met has 3 isomers: P08581-1: 155541 Da (predicted); P08581-2: 157712 Da (predicted); P08581-3: 85745 Da (predicted).
Autophosphorylated in response to ligand binding on Tyr-1234 and Tyr-1235 in the kinase domain leading to further phosphorylation of Tyr-1349 and Tyr-1356 in the C-terminal multifunctional docking site. Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365. Dephosphorylated by PTPN1 and PTPN2;Ubiquitinated. Ubiquitination by CBL regulates MET endocytosis, resulting in decreasing plasma membrane receptor abundance, and in endosomal degradation and/or recycling of internalized receptors;O-mannosylation of IPT/TIG domains by TMEM260 is required for protein maturation (PubMed:37186866). O-mannosylated residues are composed of single mannose glycans that are not elongated or modified (PubMed:37186866);(Microbial infection) Tyrosine phosphorylation is stimulated by L.monocytogenes InlB. Tyrosine phosphorylation is maximal 10-20 minutes after treatment with InlB and disappears by 60 minutes. The phosphorylated residues were not identified

Heterodimer made of an alpha chain (50 kDa) and a beta chain (145 kDa) which are disulfide linked. Binds PLXNB1. Interacts when phosphorylated with downstream effectors including STAT3, PIK3R1, SRC, PCLG1, GRB2 and GAB1.

P08581

MET; Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met